Category: Uncategorized

We are thrilled to announce that Orbit Genomics has been selected for the inaugural cohort of startups in CancerX’s Accelerator program! CancerX is a public-private partnership announced by The White House as a national accelerator to boost innovation in the fight against cancer as part of the reignited Cancer Moonshot. A team of Accelerator Champions…

We’re thrilled to announce we’ve been named a Deep Tech Pioneer by Hello Tomorrow! Out of an astonishing 4,500 applications from 120 countries, Orbit Genomics stood out as one of the most promising in the realm of deep tech. Come and meet us at the Hello Tomorrow Global Summit in March 2024, the cornerstone event…

We are thrilled to announce that Orbit Genomics has partnered with the esteemed Icahn School of Medicine at Mount Sinai for optimization of our revolutionary lung cancer diagnostic platform. This collaboration will allow us to further advance the accuracy and reliability of our test, which will have significant implications for the future of cancer diagnosis…

https://www.einpresswire.com/article/559943576/orbit-genomics-raises-3-million-to-launch-a-lung-cancer-diagnostic-test

https://oedit.colorado.gov/press-release/86-million-advanced-industries-awards-accelerate-36-colorado-start-ups

https://www.prnewswire.com/news-releases/plug-and-play-accepts-130-startups-for-their-winter-2019-batches-300925759.html?tc=eml_cleartime

https://www.cobioscience.com/events-calendar/RMLIPC2019

Researchers in Blacksburg Develop Lung Cancer Risk Genetic Test

Orbit Genomics Co-Founder and CSO, Dr. Harold “Skip” Garner, is the senior author on a paper appearing in Oncogene (31 July 2017) entitled “High-depth, high-accuracy microsatellite genotyping enables precision lung cancer risk classification” and can be viewed at http://rdcu.be/uCMU. Early detection and screening for lung cancer can help overcome the high incidence and poor survival rates of this deadly disease.…